Scarica l'app Stockscreener
52.59
0.07%
-0.036
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Soleno Therapeutics Inc Borsa (SLNO) Ultime notizie
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
SLNO SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026 - PR Newswire
Trading the Move, Not the Narrative: (SLNO) Edition - Stock Traders Daily
2026-04-12 | SLNO STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Soleno Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:SLNO | Press Release - Stockhouse
NASDAQ: SLNO: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Soleno Therapeutics, Inc. - The Globe and Mail
FinancialContentNASDAQ: SLNO: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Soleno Therapeutics, Inc. - FinancialContent
SLNO INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026 - marketscreener.com
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionSLNO - ACCESS Newswire
Soleno Therapeutics, Inc. Notice of May 5, 2026 Application Deadline for Class Action LawsuitContact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline - PR Newswire
Neurocrine Biosciences, Inc. (NBIX) Soleno Therapeutics, Inc.M&A CallSlideshow (NASDAQ:NBIX) 2026-04-10 - Seeking Alpha
SLNO Shareholder Alert: Soleno Therapeutics, Inc. Securities Class Action Lawsuit Investors ... - Bluefield Daily Telegraph
SLNO Shareholder Alert: Soleno Therapeutics, Inc. - GlobeNewswire
INVESTOR NOTICE: Soleno Therapeutics (SLNO) Investors with Substantial Losses Have Opportunity to Lead Investor Class ActionHagens Berman - Sahm
TD Cowen Downgrades Soleno Therapeutics to 'Hold' - National Today
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Super Micro Computer, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
SLNO DEADLINE NOTICE: Soleno Therapeutics, Inc. Investors Encouraged to Contact Kirby McInerney LLP By May 5, 2026 - ACCESS Newswire
Rosen Law Firm Encourages Soleno Therapeutics Investors to Secure Counsel Before Deadline - National Today
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Soleno Therapeutics, Inc. Investors with ... - Caledonian Record
ROSEN, A LEADING LAW FIRM, Encourages Eos Energy Enterprises, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – EOSE - GlobeNewswire Inc.
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages - GlobeNewswire
SLNO Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026 - marketscreener.com
SOLENO LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Announces - GlobeNewswire
Soleno Therapeutics Investors Seek Lead in Class Action Lawsuit - National Today
INVESTOR NOTICE: Soleno Therapeutics (SLNO) Investors with Subst - GuruFocus
Bronstein, Gewirtz & Grossman LLC Urges Soleno - GlobeNewswire
Soleno Therapeutics Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Soleno Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesSLNO - PR Newswire
SOLENO THERAPEUTICS, INC. (SLNO) DEADLINE ALERT Bernstein - GlobeNewswire
Soleno Therapeutics (SLNO) still appears attractive despite slower US launch ramp projections - MSN
Soleno Therapeutics Downgraded to 'Hold' by Cantor Fitzgerald - National Today
United StatesGoodwin Advises Centerview And Guggenheim On $2.9 Billion Sale Of Soleno Therapeutics To Neurocrine Biosciences - Mondaq
This Soleno Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Sahm
Soleno Therapeutics, Inc. INVESTIGATION: Kirby McInerney LLP Anno - The National Law Review
Soleno Therapeutics Inc. (SLNO) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit – RGRD Law - marketscreener.com
INVESTOR ALERT: Soleno Therapeutics Inc. (SLNO) Investors - GlobeNewswire
SLNO Stockholders Have Opportunity to Lead Soleno Therapeutics, I - The National Law Review
Soleno Therapeutics, Inc. (SLNO) Investors: May 5, 2026, Deadline in Securities Fraud Class Action Lawsuit - Morningstar
SLNO ALERT: Hagens Berman Alerts Soleno (SLNO) Investors to - GlobeNewswire
Soleno Therapeutics (NASDAQ:SLNO) Tracks Rating Downgrade Amid Nasdaq Index Activity - Kalkine Media
Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Soleno Therapeutics Stock Rallies 56.4% in a Week: Here's Why - Yahoo Finance
SLNO Stockholders Have Opportunity to Lead Soleno Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
HC Wainwright & Co. downgrades Soleno Therapeutics (SLNO) - MSN
A Look At Soleno Therapeutics (SLNO) Valuation After Its Recent Share Price Surge - Sahm
Soleno Therapeutics, Inc. Notice of May 5, 2026 Application - GlobeNewswire
Gemini Space Station, Inc. Notice of May 18, 2026 Application Deadline for Class Action Lawsuit - GlobeNewswire Inc.
Enphase Energy, Inc. Notice of April 20, 2026 Application Deadline for Class Action Lawsuit - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Soleno Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – SLNO - ChartMill
Neurocrine Grows in Endocrinology, Rare Disease with $2.9B Soleno Buyout - Genetic Engineering and Biotechnology News
SLNO Investor Alert: Soleno Therapeutics, Inc. Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Company Allegedly Concealed Commercial Viability Risks: Levi & Korsinsky - Business Wire
Neurocrine’s $2.9B Soleno Buyout Brings What Could Become Its Next Blockbuster Drug - Dealbreaker
SLNO SHAREHOLDER UPDATE: Soleno (SLNO) Facing Securities Class Action After DCCR Launch Setback, Share Drop-- Hagens Berman - PR Newswire
Deadline Alert: Soleno Therapeutics, Inc. (SLNO) - GlobeNewswire
SOLENO THERAPEUTICS, INC. (SLNO) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Soleno Therapeutics, Inc. Investors of Upcoming Deadline - TMX Newsfile
Analysts Offer Insights on Healthcare Companies: Soleno Therapeutics (SLNO) and Viridian Therapeutics (VRDN) - The Globe and Mail
Baird Downgrades Soleno Therapeutics to Neutral From Outperform, Cuts Price Target to $53 From $107 - Moomoo
Neurocrine Soleno Deal Adds Vykat XR And Alters Valuation Story - Yahoo Finance
Soleno Therapeutics: A Masterclass in Rare Disease Redemption and the $2.9B Exit - FinancialContent
Company News for Apr 7, 2026 - Yahoo Finance
SLNO Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Soleno Therapeutics, Inc. Securities Lawsuit -- The Gross Law Firm - ChartMill
Soleno Therapeutics Pulls Europe Drug Filing After $2.9 Billion Neurocrine Deal - TechStock²
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Oppenheimer Downgrades Soleno Therapeutics to Market Perform From Outperform - Moomoo
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion | Vykat XRNews and Statistics - IndexBox
Neurocrine Biosciences Weighs Soleno Deal To Broaden CNS Portfolio - simplywall.st
Soleno Therapeutics withdraws European application for PWS treatment By Investing.com - Investing.com South Africa
Soleno Withdraws EU Application for Prader-Willi Treatment - TipRanks
TD Cowen Downgrades Soleno Therapeutics to Hold From Buy, Adjusts PT to $53 From $85 - marketscreener.com
Soleno Therapeutics withdraws European application for PWS treatment - Investing.com
Soleno Therapeutics Incwithdraws marketing authorization application for Viokat in EuropeSEC filing - marketscreener.com
Soleno Therapeutics withdraws EU marketing application for VIOKAT (VYKAT XR) - TradingView — Track All Markets
0.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):